|
|
|
|
| LEADER |
00000nab a2200000 a 4500 |
| 001 |
vtls000804228 |
| 003 |
SK-MaSNL |
| 005 |
20260319074832.0 |
| 008 |
140619c1999 xo 0 eng |
| 015 |
|
|
|a SNBRB2002/09-26972
|
| 035 |
|
|
|a CLN000155883
|
| 040 |
|
|
|a SNKBUCL
|b slo
|c SNKBUCL
|e AACR2
|
| 041 |
0 |
|
|a eng
|
| 044 |
|
|
|a xo
|c SK
|
| 080 |
|
|
|a 615.7:616-006
|2 1997
|
| 100 |
1 |
|
|a Ghosh, M.
|4 aut
|9 843214
|
| 245 |
1 |
0 |
|a Evalution of 2-(methylaminosulfonyl)-1-(arylsulfonyl)- hydrazines as anticancer antigens
|c M. Ghosh, S. Gutta, V. Sanyal
|
| 300 |
|
|
|b Tab.
|
| 504 |
|
|
|a Res. angl.
|
| 504 |
|
|
|a Bibliogr. odkazy
|
| 650 |
0 |
7 |
|a chemoterapia adjuvantná
|2 snkbucl
|9 843215
|
| 650 |
0 |
7 |
|a bunky nádorové kultivované
|2 snkbucl
|9 843216
|
| 650 |
0 |
7 |
|a nádory, klasifikácia podľa štádia
|2 snkbucl
|9 843217
|
| 650 |
0 |
7 |
|a cytotoxíny
|2 snkbucl
|9 843218
|
| 650 |
0 |
7 |
|a myši
|2 snkbucl
|9 20989
|
| 650 |
0 |
7 |
|a cytostatiká
|x nežiadúce účinky
|x farmakokinetika
|x imunológia
|2 snkbucl
|9 843219
|
| 655 |
|
7 |
|a články z novín a časopisov
|2 snkbucl
|9 267496
|
| 700 |
1 |
|
|a Gutta, S.
|4 aut
|9 843220
|
| 700 |
1 |
|
|a Sanyal, V.
|4 aut
|9 843221
|
| 773 |
0 |
|
|t Neoplasma
|g Roč. 46, č. 4 (1999), s. 242-245
|x 0028-2685
|
| 850 |
|
|
|a Slovenská národná knižnica v Martine
|
| 852 |
|
|
|a SNK
|b KIS3GCP
|
| 958 |
|
|
|a NB
|
| 958 |
|
|
|a MI
|
| 992 |
|
|
|a RBX
|
| 999 |
|
|
|c 1360107
|d 1362037
|
